Eli Lilly & Co. v. Medtronic, Inc.

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Eli Lilly & Co. v. Medtronic, Inc.
Argued February 26, 1990
Decided June 18, 1990
Full case nameEli Lilly and Company v. Medtronic, Inc.
Docket no.89-243
Citations496 U.S. 661 (more)
110 S. Ct. 2683; 110 L. Ed. 2d 605; 1990 U.S. LEXIS 3184; 58 U.S.L.W. 4838; 15 U.S.P.Q.2d (BNA) 1121
Case history
PriorJudgment for plaintiff, 696 F. Supp. 1033 (E.D. Pa. 1988); reversed, 872 F.2d 402 (Fed. Cir. 1989); rehearing en banc denied, 879 F.2d 849 (Fed. Cir. 1989); cert. granted, 493 U.S. 889 (1989).
SubsequentRehearing Denied, August 14, 1990, 1990 U.S. LEXIS 3730; remanded to District Court, 915 F.2d 670 (1990).
Holding
Section 271(e)(1) exempts from infringement the use of patented inventions reasonably related to the development and submission of information needed to obtain marketing approval of medical devices under the FDCA.
Court membership
Chief Justice
William Rehnquist
Associate Justices
William J. Brennan Jr. · Byron White
Thurgood Marshall · Harry Blackmun
John P. Stevens · Sandra Day O'Connor
Antonin Scalia · Anthony Kennedy
Case opinions
MajorityScalia, joined by Rehnquist, Brennan, Marshall, Blackmun, Stevens
DissentKennedy, joined by White
O'Connor took no part in the consideration or decision of the case.
Laws applied
35 U.S.C. § 271

Eli Lilly and Company v. Medtronic, Inc., 496 U.S. 661 (1990), is a United States Supreme Court case related to patent infringement in the medical device industry. It held that 35 U.S.C. § 271(e)(1)[1] of United States patent law exempted premarketing activity conducted to gain approval of a device under the Federal Food, Drug, and Cosmetic Act from a finding of infringement.[2]

See also[edit]

References[edit]

  1. ^ 35 U.S.C. § 271(e)(1).
  2. ^ Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990).

External links[edit]